DGAP-News: LeenLife Pharma International Inc

DGAP-News: LeenLife Pharma International: Corporate Updates

DGAP-News: LeenLife Pharma International Inc. / Key word(s): Miscellaneous LeenLife Pharma International: Corporate Updates

18.05.2016 / 15:00 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Vancouver, British Columbia--(Newsfile Corp. - May 18, 2016) - LeenLife Pharma International Inc. (CSE: LLP) (the 'Company') is pleased to announce the appointment of several professional advisors and consultants to support the management team and the buildup of the LeenLife products. Edward J Ulrich is a Professional Engineer having graduated from the University of Toronto in 1983. Edward has comprehensive experience in designing and building industrial equipment, understanding construction processes and manufacturing and implementation methods. Edward is experienced in all the stages of a product, including research, development, manufacture, marketing, right through to installation, final commissioning and sales. We look forward to working with Edward to set up new programs to coordinate with our products. Elizabeth Liu obtained her undergraduate degree from McGill University and her law degree from the University of British Columbia. She was called to the Bar of British Columbia in 1991. Elizabeth was the Managing Partner at Basham Thompson & Liu LLP (now part of Owen Bird), practising civil litigation. Elizabeth's interest in business and management led her to Flora Manufacturing & Distributing Ltd. where she was appointed the company's Vice-President & General Counsel. Flora manufactures and distributes premium natural health products and has distributorships in over 30 countries. As Vice-President and General Counsel. Elizabeth was involved in all aspects of the business operations of the company in addition to overseeing the company's legal risk management processes. Elizabeth brings 25 years of legal and management experience to LINK Business Law Group, a firm which addresses the business needs of companies by providing strategic and legal risk management advice as well as general counsel services. Her clients include both start-up and established companies in a number of industries. Carl F. Perez received his Ph.D. in Biophysics from the University of California, Berkeley in 1984. He has a distinguished leadership record in academic research programs, and biologics and drug development with 30 years of research-team supervision and leadership in the pharmaceutical industry. Carl is experienced in all phases of drug discovery, technology transfer, process development, biological assay development, preclinical development, medical diagnostics, manufacturing and clinical support. He possesses a broad scientific background in cancer, immunology, molecular biology, and inflammation; and is a co-inventor on 18 issued US patents. Carl is providing scientific and technical support to the Company. The Company has amended the acquisition agreement pursuant to the acquisition of 90% of LeenLife Pharma S.A. (Poland) so that a cash payment of $563,000 is now due on or before November 24, 2016, which date was mutually agreed between the parties. About LeenLife LeenLife has developed a patented process to isolate omega-3 fatty acids from flax seeds. LeenLife products have been developed and researched for over 17 years. For additional information see our website at http://leenlifepharma.com. For more information, please contact: Stan Lis, CEO Tel: 604 764-0518 E-mail: slis@leenlifepharma.com

Click on, or paste the following link into your web browser, to view the associated documents

http://www.newsfilecorp.com/release/20668

News Source: Newsfile

---------------------------------------------------------------------------

18.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: LeenLife Pharma International Inc. Canada ISIN: CA5242751041 End of News DGAP News Service ---------------------------------------------------------------------------

464683 18.05.2016